Cited by 283Fatty Acid Research and HealthInflammatory mediators and NSAID effectsEicosanoids and Hypertension Pharmacology

Resolvin D1 Receptor Stereoselectivity and Regulation of Inflammation and Proresolving MicroRNAs

Open access
Krishnamoorthy, Sriram, Recchiuti, Antonio, Chiang, Nan, Fredman, Gabrielle, Serhan, Charles N.·2012·The American Journal of Pathology

Abstract

Resolution of acute inflammation is an active process that involves the biosynthesis of specialized proresolving lipid mediators. Among them, resolvin D1 (RvD1) actions are mediated by two G protein-coupled receptors (GPCRs), ALX/FPR2 and GPR32, that also regulate specific microRNAs (miRNAs) and their target genes in novel resolution circuits. We report the ligand selectivity of RvD1 activation of ALX/FPR2 and GPR32. In addition to RvD1, its aspirin-triggered epimer and RvD1 analogs each dose dependently and effectively activated ALX/FPR2 and GPR32 in GPCR-overexpressing β-arrestin systems using luminescence and electric cell-substrate impedance sensing. To corroborate these findings in vivo, neutrophil infiltration in self-limited peritonitis was reduced in human ALX/FPR2-overexpressing transgenic mice that was further limited to 50% by RvD1 treatment with as little as 10 ng of RvD1 per mouse. Analysis of miRNA expression revealed that RvD1 administration significantly up-regulated miR-208a and miR-219 in exudates isolated from ALX/FPR2 transgenic mice compared with littermates. Overexpression of miR-208a in human macrophages up-regulated IL-10. In comparison, in ALX/FPR2 knockout mice, RvD1 neither significantly reduced leukocyte infiltration in zymosan-induced peritonitis nor regulated miR-208a and IL-10 in these mice. Together, these results demonstrate the selectivity of RvD1 interactions with receptors ALX/FPR2 and GPR32. Moreover, they establish a new molecular circuit that is operative in the resolution of acute inflammation activated by the proresolving mediator RvD1 involving specific GPCRs and miRNAs.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ajpath.2012.01.028

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 52 references couldn’t be matched to a known paper.

Research works printed but not linked: 3

  1. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac RL: Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002, 196:1025-1037
  2. Jin Y, Arita M, Zhang Q, Saban DR, Chauhan SK, Chiang N, Serhan CN, Dana MR: Novel anti-inflammatory and pro-resolving lipid medi- ators block inflammatory angiogenesis. Invest Ophthalmol Vis Sci 2009, 50:4743-4752
  3. Krishnamoorthy et al AJP May 2012, Vol. 180, No.

Cited by

Sorted by citations

Authors
Krishnamoorthy, S., Recchiuti, A., Chiang, N., Fredman, G., & Serhan, C. N.
Affiliations
Brigham and Women's Hospital (US)
Corresponding author
Serhan, Charles N.
Venue
The American Journal of Pathology
Publisher
Elsevier BV
Published
2012-05
Volume
180
Issue
5
Pages
2018-2027
ISSN
0002-9440 (ISSN-L)
OpenAlex
W2119001835
Cited by
283
References
52
Citations by year
2026: 17 · 2025: 11 · 2024: 11 · 2023: 17 · 2022: 18 · 2021: 31 · 2020: 22 · 2019: 27 · 2018: 23 · 2017: 23 · 2016: 18 · 2015: 20 · 2014: 21 · 2013: 18 · 2012: 6
FWCI
19.33
Type
journal article
Language
en
Open access
Locations
  • American Journal Of Pathology (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Brigham and Women's Hospital
  • Queen Mary University of London
  • National Institutes of Health (GM038765)
  • National Institute of General Medical Sciences (R01GM038765)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Pharmacology › Inflammatory mediators and NSAID effects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
Keywords
resolvin D1, FPR2/ALX, inflammation resolution, specialized pro-resolving mediators, microRNA regulation, miR-208a, miR-219, IL-10, neutrophil infiltration, peritonitis, macrophages, beta-arrestin
MeSH terms
beta-Arrestins, Acute Disease, Animals, Cells, Cultured, Docosahexaenoic Acids, Dose-Response Relationship, Drug, Gene Expression Regulation, Humans, Inflammation, Ligands, Macrophages, Mice, Transgenic, Peritonitis, Up-Regulation, Interleukin-10, Electric Impedance, Mice, Knockout, Arrestins, Neutrophil Infiltration, MicroRNAs, Receptors, G-Protein-Coupled, Receptors, Formyl Peptide, Receptors, Lipoxin, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review